Literature DB >> 10980858

The impact of recent ion channel science on the development and use of antiarrhythmic drugs.

M N Langan1.   

Abstract

In the past 20 years in the basic laboratory, tools have been developed to further our understanding of the mechanism of arrhythmias and of the effect of compounds on these or their substrates. Patch clamp studies have better defined the cardiac channels. A new classification of antiarrhythmic drugs was devised, coined the Sicilian Gambit. Drugs, aimed at blocking specific channels, are now being developed. With the cloning of channels, information about their molecular structure became available. One can begin to understand the molecular determinants of antiarrhythmic drug action on specific ion channels, and how this is modulated by effectors. Molecular and electrophysiologic techniques also have been used to collect information about the way disease states affect the cardiac channels, and how this can alter the response to ion channel blockers. This has proceeded utilizing a few technologies. Diseased heart cells from patients, from animal models of disease, or from transgenic mice are studied to examine the change in current expression and channel protein quantity in different stages of disease. Hopefully this new information will make drug therapy more target-oriented.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10980858     DOI: 10.1007/s11886-999-0054-4

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  29 in total

Review 1.  Ion channels--basic science and clinical disease.

Authors:  M J Ackerman; D E Clapham
Journal:  N Engl J Med       Date:  1997-05-29       Impact factor: 91.245

Review 2.  Anisotropic activation spread in heart cell monolayers assessed by high-resolution optical mapping. Role of tissue discontinuities.

Authors:  V G Fast; B J Darrow; J E Saffitz; A G Kléber
Journal:  Circ Res       Date:  1996-07       Impact factor: 17.367

3.  Use-dependent block of the delayed K+ current in rabbit ventricular myocytes.

Authors:  E Carmeliet
Journal:  Cardiovasc Drugs Ther       Date:  1993-08       Impact factor: 3.727

4.  Repolarization abnormalities, arrhythmia and sudden death in canine tachycardia-induced cardiomyopathy.

Authors:  P H Pak; H B Nuss; R S Tunin; S Kääb; G F Tomaselli; E Marban; D A Kass
Journal:  J Am Coll Cardiol       Date:  1997-08       Impact factor: 24.094

5.  Protection against programmed electrical stimulation-induced ventricular tachycardia and sudden cardiac death by NE-10064, a class III antiarrhythmic drug.

Authors:  S C Black; J L Butterfield; B R Lucchesi
Journal:  J Cardiovasc Pharmacol       Date:  1993-12       Impact factor: 3.105

6.  Abnormal electrical properties of myocytes from chronically infarcted canine heart. Alterations in Vmax and the transient outward current.

Authors:  W M Lue; P A Boyden
Journal:  Circulation       Date:  1992-03       Impact factor: 29.690

7.  Class III antiarrhythmic drug action in experimental atrial fibrillation. Differences in reverse use dependence and effectiveness between d-sotalol and the new antiarrhythmic drug ambasilide.

Authors:  J Wang; J Feng; S Nattel
Journal:  Circulation       Date:  1994-10       Impact factor: 29.690

8.  Ionic mechanism of action potential prolongation in ventricular myocytes from dogs with pacing-induced heart failure.

Authors:  S Kääb; H B Nuss; N Chiamvimonvat; B O'Rourke; P H Pak; D A Kass; E Marban; G F Tomaselli
Journal:  Circ Res       Date:  1996-02       Impact factor: 17.367

9.  ECG T-wave patterns in genetically distinct forms of the hereditary long QT syndrome.

Authors:  A J Moss; W Zareba; J Benhorin; E H Locati; W J Hall; J L Robinson; P J Schwartz; J A Towbin; G M Vincent; M H Lehmann
Journal:  Circulation       Date:  1995-11-15       Impact factor: 29.690

10.  Genetically defined therapy of inherited long-QT syndrome. Correction of abnormal repolarization by potassium.

Authors:  S J Compton; R L Lux; M R Ramsey; K R Strelich; M C Sanguinetti; L S Green; M T Keating; J W Mason
Journal:  Circulation       Date:  1996-09-01       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.